No Cover Image

Journal article 204 views 57 downloads

Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

Esteban Jódar, Marie Michelsen, William Polonsky, Rosangela Réa, Anna Sandberg, Tina Vilsbøll, Mark Warren, Signe Harring, Uwe Ziegler, Steve Bain Orcid Logo

Diabetes, Obesity and Metabolism

Swansea University Author: Steve Bain Orcid Logo

  • 54313VOR.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).

    Download (1.08MB)

Check full text

DOI (Published version): 10.1111/dom.14039

Published in: Diabetes, Obesity and Metabolism
ISSN: 1462-8902 1463-1326
Published: Wiley 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa54313
Tags: Add Tag
No Tags, Be the first to tag this record!
Keywords: cardiovascular disease, GLP-1 analogue, hypoglycaemia, incretin therapy, type 2 diabetes,weight control